CVS Joins Express Scripts in Targeting New Cholesterol Drugs
This article is for subscribers only.
CVS Health Corp., the second-biggest manager of prescription drug benefits in the U.S., will make a new class of injectable cholesterol treatments its next major target to push back against high drug costs.
The drugs, called PCSK9 inhibitors, belong to an experimental class of medicines under development by Amgen Inc., Pfizer Inc., and Sanofi and Regeneron Pharmaceuticals Inc. They can cut levels of LDL, or bad, cholesterol dramatically, benefiting people who can’t take other cholesterol medicines or who can’t get their levels low enough.